Key points in brief
- The market access director leads the effort to obtain reimbursement and pricing for a medicine from French and European health authorities.
- The role deals with three institutional counterparts: the French National Authority for Health, the Economic Committee for Health Products and the national health insurance fund.
- The position is reached after eight to ten years of experience, with a master’s level degree at minimum in health economics, pharmacy or public affairs.
- Compensation ranges from 90 to 130 K€ gross per year, and exceeds 160 K€ on European or international scopes.
- The European regulation on health technology assessment, applicable since January 2025, has substantially changed how dossiers are prepared.
Written by the consultants at CDG Conseil, recruitment firm for the pharmaceutical industry. Updated: 01 Sept. 2026
What is market access in the pharmaceutical industry?
Market access covers everything that allows a medicine to be reimbursed, priced and genuinely available to patients. Obtaining authorisation to market a product is not enough: it still has to be covered by the health system, at a price that makes commercialisation viable. That is exactly the territory of market access.
Market access or “accès au marché”: what are we talking about
Both expressions describe the same function. “Accès au marché” is the official French translation used in occupational reference frameworks, but almost every pharmaceutical company uses the English term, including in its org charts and job titles.
One useful clarification for candidates searching online: in international trade, “market access” also refers to access to export markets and customs issues. The two worlds have nothing in common, which explains the frequent confusion in search results.
Market access and regulatory affairs: two distinct functions
The confusion comes up regularly, including among experienced candidates. Regulatory affairs obtains the marketing authorisation, in other words the right to sell. Market access obtains reimbursement and pricing, in other words the actual ability to sell.
The two functions work in sequence and coordinate early on, but the skills are not the same: regulatory rests on documentary compliance, market access on health economics and institutional negotiation. For the regulatory side, see our job profile on regulatory affairs in the pharmaceutical industry.
Why the function has gained weight
The rise of market access in org charts is explained first of all by the price of innovative therapies. In oncology as in gene therapy, the levels reached make proof of value unavoidable. Payers now demand health economic evidence that the clinical dossier alone does not provide. And spending controls have tightened, shifting the challenge from market authorisation towards negotiation.
The role and reporting line of the market access director
The market access director defines and drives the market access strategy for the entire product portfolio, from development phases through to the maintenance of coverage. They represent the company before health authorities and arbitrate between the company’s economic objectives and payer expectations.
Reporting line
The position most often reports to general management, to medical affairs, or to a corporate market access function in international groups. The reporting line matters: a market access function attached to medical affairs will have a scientific centre of gravity, while a direct line to general management means a seat on the executive committee and real weight in portfolio decisions.
This is one of the first points we clarify when scoping an assignment, because it determines which candidate profile to approach.
France, Europe or global scope
A France market access director manages relations with the French National Authority for Health and the Economic Committee for Health Products. A European or global scope means coordinating affiliates across heterogeneous healthcare systems, building international reference pricing strategies and managing launch sequencing country by country. The compensation gap between the two configurations is significant.
The responsibilities of the market access director
The responsibilities of the market access director cover building the access strategy, submitting assessment dossiers to health authorities, negotiating pricing, producing evidence of value and managing the pricing, health economics and public affairs teams.
Building the access strategy from the development stage
Access strategy is prepared years ahead of launch. The market access director contributes to clinical trial design to ensure that the comparators, endpoints and populations selected will be acceptable to assessors. A methodologically flawless study can still be judged insufficient by the French National Authority for Health if the chosen comparator is not the one used in French practice.
Managing the transparency dossier
The dossier submitted to the Transparency Committee of the French National Authority for Health determines two decisive ratings: the actual clinical benefit, which sets the reimbursement rate, and the improvement in actual clinical benefit, which sets the room for negotiation on price. For products with a high budget impact, a health economic assessment conducted by the dedicated committee is added to this.
An improvement rating of level V, meaning no demonstrated progress, closes almost every pricing door. Most of the market access director’s work consists of avoiding that outcome.
Negotiating the price with the CEPS
The negotiation with the Economic Committee for Health Products covers the list price, but also rebates, volume clauses and risk sharing mechanisms. These agreements are confidential, which explains why the published price of a medicine rarely reflects its real price.
This phase calls for institutional negotiation skills that cannot be learned in a training course. It is the area where candidates are hardest to substitute.
Building the value proposition and using real world data
The market access director assembles the product’s value argument: clinical benefit, organisational impact, savings generated, response to an unmet need. Real world data plays a growing part in this demonstration, particularly for reassessments and for products that have benefited from early access.
Leading the teams
Depending on the size of the company, the director leads teams in pricing, health economics and outcomes research, public affairs and payer relations. In leaner structures, particularly in biotech, they handle part of these responsibilities personally, which completely changes the profile being sought.
Anticipating current reforms
Several recent developments weigh directly on the day-to-day work of market access teams in France.
The European regulation on health technology assessment, applicable since January 2025, introduces a joint clinical assessment at European level. It covers oncology medicines and advanced therapy medicinal products first, with progressive extension planned to orphan medicines and then to all medicines. In practice, part of the clinical analysis now takes place upstream and jointly, while the appraisal of value and price setting remain national. This does not reduce the workload of French teams, it shifts it and moves it earlier in the calendar.
The reform of derogatory access, which came into force in 2021, replaced temporary authorisations for use with early access and compassionate access schemes. It changed the sequence of availability and created a new challenge: data collected during the early access period then feeds the standard dossier.
Finally, the mechanisms regulating pharmaceutical spending, including the safeguard clause, have become a strategic parameter. They are not solely a matter for the finance function: they influence launch decisions and negotiating positions.
For a candidate, having managed a dossier under these new regimes is now a clear point of differentiation.
Roles within the market access career path
The market access career path runs from market access associate through to director, with an intermediate manager level. Specialist functions in health economics, pricing and public affairs sit alongside it.
| Job title | Experience | Scope |
|---|---|---|
| Market Access Officer | 0 to 3 years | Contributing to dossiers, monitoring developments, market and price analysis |
| Market access manager | 3 to 8 years | Managing a product’s dossier, preparing for negotiations |
| Market access director | 8 to 10 years and over | Portfolio strategy, CEPS negotiations, supervision, executive committee |
Adjacent functions
Several specialisms revolve around market access and act as a recruitment pool. Health economics and outcomes research produce the health economic models and budget impact analyses. Pricing builds pricing strategies, including international ones. Public affairs manages relationships with institutions and patient associations.
A market access director almost always comes from one of these areas. Rarely from product marketing.
What salary for a market access director?
Compensation for a market access director in the pharmaceutical industry ranges from 90 to 130 K€ gross per year on a France scope, and exceeds 160 K€ on positions with a European or international dimension, depending on management responsibilities and experience.
| Level | Experience | Observed Gross Annual Compensation |
|---|---|---|
| Market Access Specialist | 0 to 3 years | between 40 K€ and 50 K€ |
| Market Access Manager | 3 to 8 years | between 55,000€ and 90,000€ |
| Market Access Director, France | 8 to 10 years and more | between 90,000€ and 130,000€ |
| Market Access Director, Europe or International | 10 years and more | Up to 160,000€ and above |
Ranges observed by CDG Conseil on assignments handled in the pharmaceutical industry. Last updated: September 2026.
What makes compensation vary
At equivalent level, geographic scope remains the most decisive factor. Next come portfolio size and the presence of high value products or first-time listings, which expose the postholder more. The variable component is generally significant on these roles, and biotechs sometimes offset a more modest base salary with equity incentive schemes.
Skills and profile sought
A market access director must master how the French healthcare system works, health economics and price setting mechanisms, and must be able to negotiate with institutional counterparts in situations where the balance of power is not in their favour.
Technical skills
- How the French National Authority for Health, the Economic Committee for Health Products and the national health insurance fund operate
- Health economic assessment, cost modelling, budget impact analysis
- Building and defending a transparency dossier
- Contractual negotiation: rebates, volume clauses, risk sharing
- Real world data and the associated methodologies
- European framework for health technology assessment
- Fluent professional English, including presenting to an international committee
What separates two candidates in interview
On these roles, technical knowledge is a prerequisite, not a deciding factor. What decides is the ability to hold a position in front of a health authority without breaking the relationship, to translate a health economic model for an executive committee that does not master its assumptions, and to own an unfavourable decision without passing it back to the clinical teams.
The international dimension
International companies expect genuine ease in English, particularly spoken and in presentation settings. It is a frequent reason for eliminating candidates who are otherwise excellent on the French substance.
How to become a market access director
The market access director position is reached after a minimum of eight to ten years of experience in market access or in a cross-functional role exposed to institutional and economic relations, with a master’s level degree at minimum.
Initial education and specialist master’s degrees
- Master’s level: a degree in health economics, public health, public affairs, health law or pharmacy
- Doctoral level and above: a doctorate in pharmacy, medicine or science, complemented by specialist training in market access or health economics
- Dedicated master’s programmes exist, notably in market access and health economic assessment, and are the most direct route in
Typical career paths observed
Among the profiles we approach, the internal route dominates: market access associate, then manager, then director, within one or two companies. Moving through specialist consulting is the other frequent route, because it exposes people to a large number of dossiers very quickly. Then comes the move across from medical affairs or health economics, which is more common on portfolios with high scientific complexity.
Career changes
Transitions work well from medical affairs, regulatory affairs and healthcare consulting. They work considerably less well from product marketing or sales, where the absence of a health economics background shows from the first technical interview.
Possible next steps
- European or international market access director
- Government affairs director
- Health strategy and policy director
- Executive committee member
Recruiting a market access director
CDG Conseil has been recruiting market access directors and managers for pharmaceutical companies, biotechs and medical technology players, in France and internationally, since 2006.
Why this recruitment is difficult
The talent pool is narrow. The number of professionals who have genuinely conducted a negotiation with the Economic Committee for Health Products, on a product with real stakes, is counted in hundreds rather than thousands. These people are in post, visible, and approached often.
Two practical consequences follow. Direct approach is the only serious route: advertising produces nothing on this type of function. And prior scoping matters more than the search itself, because a poorly defined remit causes the recruitment to fail at the end of the process, when the candidate realises the role is not the one presented to them.
Our approach
Our assignments are run by a consultant and researcher pair. On leadership functions, we work in executive search, with a systematic scoping phase before any search begins. We also offer interim management solutions when an access dossier has to be carried through a vacancy, a frequent situation given recruitment timescales on these roles.
This pressure is part of a wider movement that we document in our analysis of demographic change among Life Sciences talent.
Paris, Lyon, Brussels and international
Market access positions are concentrated in the Paris region, where the headquarters and French affiliates of international groups are based. Our Paris and Lyon offices cover the French market, and our Brussels office handles Belgian positions as well as European functions based there, a common configuration given the proximity of the institutions.
For multi-country recruitment, we draw on the INRALS network, of which CDG Conseil is a founding member.
For Market Access Directors looking for a new role
Browse our job openings, sorted by function and updated regularly:
FAQ - Frequently asked questions about market access
What is market access?
Market access covers everything that allows a medicine to be reimbursed, priced and genuinely accessible to patients. It comes after the marketing authorisation and rests on demonstrating the product’s value to health authorities and payers.
What is the difference between market access and regulatory affairs?
Regulatory affairs obtains the marketing authorisation, in other words the right to commercialise the medicine. Market access obtains reimbursement and pricing, in other words the economic conditions that make commercialisation possible. The two functions coordinate with each other but rest on different skills.
What is the salary of a market access director?
Compensation for a market access director ranges from 90 to 130 K€ gross per year on a France scope. It exceeds 160 K€ on positions with a European or international dimension, depending on scope, management responsibilities and experience.
How do you become a market access director?
You need a master’s level degree at minimum in health economics, public health, public affairs, health law or pharmacy, then eight to ten years of experience in market access or in a cross-functional role exposed to institutional relations. Initial experience managing a team is generally required.
Why work in market access?
The function combines science, economics and institutional negotiation, with a direct and measurable impact on the availability of a medicine to patients. It offers strong exposure to general management and routes towards government affairs or health strategy.
Which authorities are involved in market access for a medicine in France?
The French National Authority for Health assesses the actual clinical benefit and the improvement in actual clinical benefit, along with the health economic dimension for products with a high budget impact. The Economic Committee for Health Products sets the price by agreement. The national health insurance fund determines the coverage rate.
What does the European HTA regulation change for market access?
Applicable since January 2025, it introduces a joint clinical assessment at European level, first for oncology medicines and advanced therapies. The appraisal of value and price setting remain national. For market access teams, this brings forward the timetable for preparing dossiers and increases the need for coordination between headquarters and affiliates.
Is market access recruiting in 2026?
Yes, with a narrow pool of profiles who have completed a pricing negotiation, worked with early access schemes or been exposed to the European framework. These recruitments go almost exclusively through direct approach.
About this job profile
Written by Céline DES HORTS, Senior Recruitment Consultant at CDG Conseil, drawing on the recruitment assignments carried out by the firm in the pharmaceutical industry. See the CDG Conseil team.
Institutional sources consulted: Haute Autorité de santé, Comité économique des produits de santé.
Published 3 April 2025. Updated 1 September 2026. This profile is reviewed every year.
